Fulcrum Therapeutics

169 articles about Fulcrum Therapeutics

• Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 11, 2022

  11/11/2022

  Fulcrum Therapeutics, Inc. announced that the Company granted non-statutory stock options to new employees as inducement awards outside of the Company’s 2019 Stock Incentive Plan.

• Fulcrum Therapeutics Announces Recent Business Highlights and Third Quarter 2022 Financial Results

  11/8/2022

  Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today reported financial results for the third quarter of 2022.

• Fulcrum Therapeutics Appoints Chief Medical Officer and Chief Scientific Officer

  11/7/2022

  Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the appointment of Santiago Arroyo, M.D., Ph.D., as Chief Medical Officer, and Jeff W. Jacobs, Ph.D., as Chief Scientific Officer.

• Fulcrum Therapeutics® to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Tuesday, November 8, 2022 at 8:00 a.m. ET

  11/2/2022

  Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that its third quarter 2022 financial results will be released on Tuesday, November 8, 2022 before the U.S. financial markets open.

• Fulcrum Therapeutics® to Participate at Upcoming November 2022 Investor Conferences

  11/1/2022

  Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that management will participate in the following upcoming investor conferences.

• 

  World Muscle Society Congress 2022: Genentech, Fulcrum and Sarepta Present Latest Findings

  10/12/2022

  The World Muscle Society 2022 Congress is ongoing in Halifax, Canada, with numerous companies presenting cutting-edge research in neuromuscular diseases. Here’s a look.

• Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 ReDUX4 Study at the World Muscle Society (WMS) Congress in Halifax, Canada

  10/12/2022

  Fulcrum Therapeutics, Inc announced today that new data from the open label extension (OLE) portion of the Phase 2 ReDUX4 study of losmapimod for the treatment of FSHD will be featured in a poster presentation at the World Muscle Society (WMS) Hybrid Congress taking place October 11-15 in Halifax, Canada.

• Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 07, 2022

  10/7/2022

  Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the Company granted non-statutory stock options to a new employee as inducement awards outside of the Company’s 2019 Stock Incentive Plan.

• Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 09, 2022

  9/9/2022

  Fulcrum Therapeutics, Inc. announced that the Company granted non-statutory stock options to new employees as inducement awards outside of the Company’s 2019 Stock Incentive Plan.

• Fulcrum Therapeutics to Participate at Upcoming September 2022 Investor Conferences

  9/6/2022

  Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that management will participate in the following upcoming investor conferences.

• Fulcrum Therapeutics® to Participate at the Upcoming Stifel 2022 Biotech Summer Summit

  8/16/2022

  Fulcrum Therapeutics, Inc. today announced that management will participate in a fireside chat at the Stifel 2022 Biotech Summer Summit, on Wednesday, August 17, 2022 at 11:30 a.m. ET.

• Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock - Aug 16, 2022

  8/16/2022

  Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced the pricing of an underwritten public offering of 9,590,792 shares of its common stock at a public offering price of $7.82 per share.

• Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock - Aug 15, 2022

  8/15/2022

  Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that it has commenced an underwritten public offering of $75 million of shares of its common stock.

• Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

  8/11/2022

  Fulcrum Therapeutics, Inc.® today reported financial results for the second quarter of 2022 and announced a strategic plan to realign internal resources to support the two clinical programs that are expected to be the key drivers of near-term value and extend cash runway.

• Fulcrum Therapeutics® to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Thursday, August 11, 2022 at 8:00 a.m. ET

  8/4/2022

  Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its second quarter 2022 financial results will be released on Thursday, August 11, 2022 before the U.S. financial markets open.

• Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 02, 2022

  8/2/2022

  Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the Company granted non-statutory stock options to new employees as inducement awards outside of the Company’s 2019 Stock Incentive Plan.

• Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 15, 2022

  7/15/2022

  Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the Company granted non-statutory stock options to new employees as inducement awards outside of the Company’s 2019 Stock Incentive Plan.

• 

  BioSpace Movers & Shakers: Astria, Apertura, CytoDyn, IN8bio & More Make Big Moves

  7/15/2022

  New leaders and top executive roles were selected to guide biopharma and life science companies from Apertura Gene Therapy to CytoDyn, Vaccentis AG, Suvoda LLC, IN8bio and more. 

• Fulcrum Phase 3 FSHD Clinical Trial using AMRA Medical's Whole-body MRI Measurements as a Key Secondary Endpoint

  7/13/2022

  REACH, a Phase 3 Clinical Trial of losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) utilizes AMRA's Muscle Fat Infiltration (MFI) as a secondary endpoint.

• Fulcrum Therapeutics Announces Departure of Chief Medical Officer

  7/11/2022

  Fulcrum Therapeutics, Inc. (Nasdaq: FULC), today announced that Chief Medical Officer, Christopher Morabito, M.D., will be leaving the company, effective July 13, 2022. Judith Dunn, Ph.D., President of Research and Development will provide interim leadership while the executive search for a new CMO is ongoing.